An erythropoietin gene polymorphism in the hypoxia-responsive element at position 3434 is possibly associated with hypertension

Kidney and Blood Pressure Research

Volumn 35, Issue 2, 2012, Pages 71-76

  Schulz, E G ^a   Neumann, C L ^a   Menne, J ^c   Schettler, V ^a   MacKenbrock, C ^a   Popov, A F ^f   Hagenah, G C ^a   Hinz, J ^b   Bargfeldt, M ^a   Gasser, T ^e   Haller, H ^c   Hermann, M ^d  

^a Center of Nephrology Göttingen   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Ambulatory blood pressure monitoring; End organ damage; Erythropoietin polymorphism; Genetics; Hypertension; Hypoxia responsive element

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYTOSINE; ERYTHROPOIETIN; THYMINE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; HYPOXIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANOXIA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; ERYTHROPOIETIN; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; STROKE; VASCULAR DISEASES;

EID: 80052585552     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000330245     Document Type: Article

References (31)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al: Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
3. Imumorin IG, Dong Y, Zhu H, Poole JC, Harshfield GA, Treiber FA, et al: A gene-environment interaction model of stress-induced hypertension. Cardiovasc Toxicol 2005;5:109-132. (Pubitemid 41058626)
4. Zhang K, Weder AB, Eskin E, O'Connor DT: Genome-wide case/control studies in hypertension: only the 'tip of the iceberg'. J Hypertens 2010;28:1115-1123.
5. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999;33:821-828.
6. Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, et al: Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004;27:79-84. (Pubitemid 38325178)
7. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, et al: Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000;97:11609-11613.
8. Kuriyama S, Tomonari H, Tokudome G, Kaguchi Y, Hayashi H, Kobayashi H, et al: Association of angiotensinogen gene polymorphism with erythropoietin- induced hypertension: a preliminary report. Hypertens Res 2001;24:501-505. (Pubitemid 33048915)
9. Lariviere R, Lebel M: Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003;81:607-621. (Pubitemid 36836395)
10. Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T: Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens 1999;12:980-987. (Pubitemid 29528697)
11. Kusano E, Akimoto T, Umino T, Yanagiba S, Inoue M, Ito C, et al: Modulation of endothelin-1-induced cytosolic free calcium mobilization and mitogen-activated protein kinase activation by erythropoietin in vascular smooth muscle cells. Kidney Blood Press Res 2001;24:192-200. (Pubitemid 32786227)
12. Liefeldt L, Schmidt-Ott KM, Orzechowski HD, Distler A, Paul M: Transcriptional regulation of endothelin-1 by erythropoietin in endothelial cells. J Cardiovasc Pharmacol 1998;31(suppl 1):S464-S466. (Pubitemid 128709982)
13. Slowinski T, Schulz N, Ruschitzka FT, Quaschning T, Bauer C, Theuring F, et al: Pattern of prepro-endothelin-1 expression revealed by reporter-gene activity in kidneys of erythropoietin-overexpressing mice. Clin Sci (Lond) 2002;103(suppl 48):44S-47S. (Pubitemid 35007118)
14. Quaschning T, Ruschitzka F, Stallmach T, Shaw S, Morawietz H, Goettsch W, et al: Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J 2003;17:259-261.
15. Varma S, Cohen HJ: Co-transactivation of the 3′ erythropoietin hypoxia inducible enhancer by the HIF-1 protein. Blood Cells Mol Dis 1997;23:169-176. (Pubitemid 27469452)
16. Goldberg MA, Dunning SP, Bunn HF: Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:1412-1415.
17. Gupta M, Mungai PT, Goldwasser E: A new transacting factor that modulates hypoxia-induced expression of the erythropoietin gene. Blood 2000;96:491-497. (Pubitemid 30463367)
18. Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M: Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998;42:913-916. (Pubitemid 28559442)
19. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-4049. (Pubitemid 32249895)
20. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al: Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004;279:20655-20662. (Pubitemid 38656460)
21. Camici GG, Stallmach T, Hermann M, Hassink R, Doevendans P, Grenacher B, et al: Constitutively overexpressed erythropoietin reduces infarct size in a mouse model of permanent coronary artery ligation. Methods Enzymol 2007;435:147-155.
22. Nishikido N, Kobayashi T, Kashiwazaki H: Hematocrit correlates with blood pressure in young male office workers. Ind Health 1999;37:76-81. (Pubitemid 29091555)
23. Percy MJ, McMullin MF, Lappin TR: Sequence analysis of the 3′ hypoxia-responsive element of the human erythropoietin gene in patients with erythrocytosis. Biochem Mol Med 1997;62:132-134. (Pubitemid 27495292)
24. 2- regulated gene expression. FASEB J 2002;16:1151-1162.
25. Camenisch G, Stroka DM, Gassmann M, Wenger RH: Attenuation of HIF-1 DNAbinding activity limits hypoxia-inducible endothelin-1 expression. Pflugers Arch 2001;443:240-249. (Pubitemid 33096128)
26. Jedlickova K, Stockton DW, Chen H, Stray-Gundersen J, Witkowski S, Ri-Li G, et al: Search for genetic determinants of individual variability of the erythropoietin response to high altitude. Blood Cells Mol Dis 2003;31:175-182.
27. Bur A, Herkner H, Vlcek M, Woisetschlager C, Derhaschnig U, Hirschl MM: Classification of blood pressure levels by ambulatory blood pressure in hypertension. Hypertension 2002;40:817-822. (Pubitemid 35434900)
28. Blanchard KL, Acquaviva AM, Galson DL, Bunn HF: Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 1992;12:5373-5385.
29. Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, et al: Fluorescence detection in automated DNA sequence analysis. Nature 1986;321:674-679. (Pubitemid 16044126)
30. Wenger RH, Rolfs A, Spielmann P, Zimmermann DR, Gassmann M: Mouse hypoxia-inducible factor-1alpha is encoded by two different mRNA isoforms: expression from a tissue-specific and a housekeeping-type promoter. Blood 1998;91:3471-3480. (Pubitemid 28193901)
31. Tsuchiya T, Okada M, Ueda M, Yasukochi Y: Activation of the erythropoietin promoter by a point mutation from GATA to TATA in the -30 region. J Biochem 1997;121:193-196. (Pubitemid 27096192)